8-K: Shattuck Labs Reports Q3 2025 Results, SL-325 Advances

Shattuck Labs announced its third quarter 2025 financial results, highlighted by the dosing of first participants in the Phase 1 clinical trial for SL-325 and a successful $103 million private placement.

Summary

• First participants were dosed in the single-ascending dose (SAD) portion of the Phase 1 clinical trial for SL-325 in healthy volunteers during the third quarter of 2025.
• A private placement of up to approximately $103 million was closed in August 2025, with proceeds, assuming full exercise of common stock warrants, expected to fund operations into 2029.
• Dan Baker, M.D., and Mona Ashiya, Ph.D., were appointed to the Board of Directors in August 2025.
• Net loss for the quarter ended September 30, 2025, was $10.1 million, or $0.14 per basic and diluted share, compared to a net loss of $16.6 million, or $0.33 per basic and diluted share, for the same period in 2024.
• Research and Development (R&D) expenses decreased to $7.6 million for Q3 2025 from $16.3 million for Q3 2024.
• General and Administrative (G&A) expenses decreased to $4.1 million for Q3 2025 from $4.6 million for Q3 2024.
• Cash and cash equivalents and short-term investments totaled $86.1 million as of September 30, 2025.

Sentiment

Score: 7

Explanation: The filing presents a positive outlook with a significant capital raise extending the cash runway and the lead candidate entering clinical trials as anticipated. Financial losses are decreasing, and R&D efficiency has improved. However, the long-term funding is contingent on warrant exercise, and the company is still in early clinical stages with no revenue from product sales.

Positives

• SL-325, a potentially first-in-class DR3 antagonist antibody, has entered clinical development with first participants dosed in Phase 1, marking a significant pipeline advancement.
• A successful private placement of up to $103 million significantly extends the cash runway into 2029, assuming full warrant exercise, providing substantial financial stability.
• Net loss decreased to $10.1 million in Q3 2025 from $16.6 million in Q3 2024, indicating improved financial performance and cost management.
• Research and Development expenses were significantly reduced to $7.6 million in Q3 2025 from $16.3 million in Q3 2024, suggesting increased efficiency in R&D spending.
• The appointments of industry experts Dan Baker, M.D., and Mona Ashiya, Ph.D., to the Board of Directors strengthen corporate governance and strategic oversight.

Negatives

• License and collaboration revenue decreased to $1.0 million for Q3 2025 from $2.997 million for Q3 2024.
• The cash runway guidance into 2029 is contingent on the full exercise of common stock warrants, which is not guaranteed and introduces a degree of uncertainty.

Risks

• Global macroeconomic conditions and related volatility could impact operations and financial performance.
• The unpredictable relationship between preclinical study results and clinical study results means that positive preclinical data may not translate to successful clinical outcomes.
• The timing or likelihood of regulatory filings and approvals for SL-325 and other candidates is uncertain.
• Liquidity and capital resources, including whether the common stock warrants will be exercised and provide additional capital, pose a risk to long-term funding.
• Other risks and uncertainties identified in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent SEC filings, could materially affect actual results.

Future Outlook

Shattuck Labs expects to complete enrollment for the single-ascending dose (SAD) and multiple-ascending dose (MAD) portions of the Phase 1 clinical trial for SL-325 by the second quarter of 2026, with initial results anticipated by the same quarter. The company also plans to announce a lead bispecific candidate from its preclinical pipeline in the first half of 2026. With the recent private placement, and assuming full warrant exercise, operations are expected to be funded into 2029, supporting advancement of SL-325 into Phase 2 trials for IBD and potentially other autoimmune diseases.

Management Comments

• "In the third quarter of 2025, SL-325 became the first DR3 blocking antibody to enter clinical development, and our Phase 1 trial is proceeding as we anticipated." Taylor Schreiber, M.D., Ph.D., Chief Executive Officer.
• "With the successful closing of our private placement, and assuming the full exercise of the common stock warrants issued in the private placement, we are well-capitalized to advance SL-325 into Phase 2 trials." Taylor Schreiber, M.D., Ph.D., Chief Executive Officer.
• "We are executing with discipline and remain focused on generating data that supports SL-325 as a potentially first-in-class DR3 blocking antibody." Taylor Schreiber, M.D., Ph.D., Chief Executive Officer.

Industry Context

Shattuck Labs is advancing SL-325 as a potentially first-in-class DR3 blocking antibody, targeting the TNF superfamily receptors for inflammatory and immune-mediated diseases like IBD. This focus on novel mechanisms within the TNF pathway positions the company in a competitive landscape where innovation in targeted therapies for autoimmune conditions is highly valued. The entry of SL-325 into clinical development as the first DR3 blocking antibody highlights a potential new frontier in treating these diseases, differentiating Shattuck from companies primarily focused on established TNF-alpha inhibitors or other inflammatory pathways.

Comparison to Industry Standards

• SL-325 is noted as the "first DR3 blocking antibody to enter clinical development," which positions it uniquely against other IBD and autoimmune disease treatments that typically target TNF-alpha (e.g., Humira, Remicade) or IL-12/23 (e.g., Stelara).
• Preclinical studies for SL-325 demonstrate "high affinity binding and superior activity over TL1A antibodies," suggesting a potentially more effective approach compared to other emerging therapies targeting the TL1A ligand.
• The cash runway into 2029, assuming full warrant exercise, provides a substantial period of funding for a clinical-stage biotech, which is generally considered strong compared to many peers who often face more frequent capital needs.

Management Changes

Stakeholder Impact

• Shareholders: Potential positive impact due to extended cash runway, advancement of lead clinical candidate, and reduced net loss. Dilution from the private placement and potential future warrant exercise.
• Employees: Continued employment and focus on key programs.
• Patients: Potential future benefit from SL-325 as a novel treatment for IBD and other inflammatory diseases.
• Creditors: Improved financial stability due to capital raise.

Next Steps

• Complete enrollment of SAD and MAD portions of Phase 1 clinical trial for SL-325 by Q2 2026.
• Disclose initial safety, tolerability, DR3 occupancy, immunogenicity, and PK data from Phase 1 clinical trial by Q2 2026.
• Advance SL-325 into Phase 2 clinical trials in IBD and potentially another autoimmune disease.
• Announce a lead bispecific candidate from the preclinical pipeline in the first half of 2026.
• Management will participate in one-on-one meetings at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025.
• CEO Taylor Schreiber will participate in a fireside chat and management will participate in one-on-one meetings at the Evercore ISI 8th Annual Healthcare Conference on December 3-4, 2025.

Key Dates

Recommendation

Shattuck Labs has made significant progress with its lead candidate SL-325 entering Phase 1 clinical trials as anticipated, and a substantial private placement has extended its cash runway into 2029, contingent on warrant exercise. The reduction in net loss and R&D expenses indicates improved operational efficiency. However, the company remains in early clinical stages, and the success of SL-325 is yet to be proven in later-stage trials. While the capital raise provides stability, the stock's performance will heavily depend on future clinical data. Given the early stage of development and the inherent risks in biotech, a 'hold' recommendation is appropriate, awaiting further clinical milestones and data readouts before a stronger stance can be taken.

Keywords

Shattuck Labs, STTK, biotechnology, DR3 blocking antibody, SL-325, Phase 1 clinical trial, IBD, inflammatory diseases, autoimmune diseases, private placement, financial results, Q3 2025 earnings, TNF superfamily receptors